Roundtables
Clinical discussions with experts in the genitourinary oncology field.
Focus on mHSPC
The panel explores the challenges involved in managing mHSPC, focusing on difficulties with obtaining PSMA scans.
The panel shares insights on managing mHSPC, emphasizing patient communication and evolving role of novel therapies.
Implementing Triplet Therapy for mHSPC: Collaboration, Patient Communication, and QOL Considerations
The panel delves into triplet therapy for mHSPC, highlighting the benefits and logistics of the ARASENS regimen.
The panel considers the decision-making process for chemo eligibility in mHSPC, emphasizing the role of patient education.
Future Directions in Metastatic PC: Exploring Monotherapy, Novel Therapies, and Strategic Sequencing
The panel ponders the future of metastatic prostate cancer treatment, emphasizing the potential of emerging therapies.
The panel concludes with thoughts on the evolving landscape of PC treatment, focusing on multidisciplinary collaboration.
Advertisement
Focus on Non-Clear Cell RCC
The panel explores our understanding of nccRCC, including classification, molecular distinctions, and prognostic criteria.
The panel focuses on CN, oligometastatic disease treatment, and advancements in systemic therapies over the past few decades.
The panel highlights recent advancements in combination therapies for nccRCC, with a focus on KEYNOTE-B61 and cabo-nivo.
The panel delves into the challenges and treatment approaches for various rare subtypes of nccRCC, including translocation.
The panel weighs the progress and challenges of adjuvant pembro and addresses the toxicity profiles of IO/TKI regimens.
The panel concludes with an overview of advancements and upcoming trials in the treatment of nccRCC.
Advertisement
Focus on RLT
The panel discusses the role of PSMA imaging in prostate cancer, theranostics, and radioligand therapy.
An expert panel discusses the evolving landscape of radioligand therapy for prostate cancer.
The third part of this roundtable explores imaging interpretation and toxicity management.
The fourth part of this roundtable delves into the VISION and PSMAfore studies and their implications.
The fifth segment of the RLT roundtable explores recent clinical trials, including the VISION study.
The challenges of patient management and access to care are explored in the sixth part of our RLT roundtable discussion.
Focus on Advanced, Metastatic RCC Sequencing, Management
The panel focuses on the final OS analysis from the JAVELIN Renal 101 trial and the challenges of combining IOs with TKIs.
The panel highlights the potential practice-changing impact of subcutaneous PD-1 agents for kidney cancer treatment.Dr.
The panel offers evolving strategies for managing treatment durations and holds for patients on IO/TKI and PD-1 regimens.
The panel emphasizes the need to decrease RCC overtreatment and to identify cured patients in the adjuvant setting.
The panel explores the latest research in rare subtypes of kidney cancer, emphasizing the need for biology-driven trials.
The panel concludes with the applications, challenges, and future prospects of belzutifan in treating advanced kidney cancer.
Focus on UTUC
The panel engages in a discussion related to risk stratification in UTUC, including identification of high-risk patients.
The panel provides a disease state overview of low-grade UTUC, including considerations for diagnosis, staging, and grading.
The panel highlights nephron-sparing approaches as well as current treatment pathways for low-grade UTUC.
The panel considers how to best treat patients with low-grade UTUC who experience disease recurrence post-surgery.
The panel dissects a longitudinal follow-up of a multicenter study of UGN-101 as well as other 2024 AUA meeting data.
The panel offers concluding thoughts on selection criteria for lymph node dissection in patients with low-grade UTUC.
Focus on RCC Treatment, Management
The panel discussed two studies that assessed adjuvant treatment: KEYNOTE-564 and CheckMate 914.
The panel shared their thoughts on the 8-year follow-up data from CheckMate 214.
The panel discussed CheckMate 9ER, which assessed quality of life outcomes in patients receiving cabozantinib/nivolumab.
The panel discussed the role of SBRT and some exciting studies like SAMURAI.
The panel discussed the impact of a subcutaneous formulation of nivolumab.
The panel shared their thoughts on quality of life data presented from the LITESPARK-005 trial of belzutifan.
The panel addressed different dosing scenarios and shared tips on how to counsel patients on their treatment.
The panel shared their excitement for the road ahead in kidney cancer.
Focus on Advanced Kidney Cancer
The panel weigh the treatment considerations of IO/IO versus IO/TKI for advanced renal cell carcinoma.
The Role of SBRT and Metastasis-Directed Therapy for RCC Treatment, Variant Histology Considerations
The panel considered the role of SBRT as well as MDT in RCC. They also weighed in on variant histology considerations.
The panel discussed the groundbreaking OS results from the KEYNOTE-564 study and implications for their practice.
The panel swapped opinions on data pertaining to CheckMate 914, CheckMate 214, and IMDC selection criteria.
The panel highlighted the CheckMate 9ER study and implications for clinical practice.
The panel transitioned to relevant considerations from the CheckMate 67T study and thoughts on subcutaneous nivolumab.
The panel forecasted some of the major questions that will be answered regarding belzutifan, triplet combinations, and more.
Focus on Clear Cell and Non-Clear Cell RCC
Dr. Plimack shared her approach to frontline clear cell kidney cancer treatment selection.
Dr. McDermott advocates for immune therapy in frontline RCC care.
Dr. Voss compares IO/IO and TKI/IO treatment options, as well as toxicity considerations.
The panel shifts to focus on the current state of non-clear cell kidney cancer.
The panel discussed important takeaways from RCC studies presented at ASCO GU.
The panel shares their outlook on the near future for renal cell carcinoma research, treatment, and care.
Focus on Metastatic Urothelial Carcinoma
The panel discussed how enfortumab vedotin and pembrolizumab figures to change the bladder cancer treatment landscape.
The panel considered treatment options for patients with mUC who are not eligible for EV/pembrolizumab.
The panel weighed in on treatment selection after patient progression on EV/pembrolizumab.
The panel transitioned to the AMBASSADOR trial findings and other adjuvant treatment considerations for urothelial carcinoma.
The panel highlighted new data released on SG, including real-world findings and relevant results from the UNITE trial.
The panel considered the latest available data pertaining to EV, atezolizumab, erdafitinib, and other therapy options.
The panel concludes with their forward-thinking thoughts on the impending direction of urothelial carcinoma treatment.
Focus on NMIBC
The panel kicked off with conversations about risk stratification and classification of low-grade, intermediate-risk disease.
The panel delves into treatment pathways, including considerations for ablation and repeated histologic evaluation.
The panel considers therapies across different risk stratifications, including ATLAS, ENVISION, and BOND-003 studies.
The panel conclude with their thoughts on considerations for TURBT and intravesical therapy versus chemoablation.
Uromigos Live & Unplugged: Bladder Cancer Roundtable
The panel discussed continued unmet needs and challenges for patients with urothelial cancer.
The panel discusses the "buzz" around the EV-302 study.
The panel discussed how the EV-302 data compare to the previous JAVELIN paradigm.
Bladder Panel Offers Insights on CheckMate 901 Study and Optimal Duration of Immunotherapy Treatment
The panel discusses the CheckMate 901 study results.
The panel shares lessons learned from the phase THOR study.
The panel discussed the double antibody-drug conjugate trial that assessed sacituzumab govitecan plus EV.
The panel shares treatment sequencing decisions based on a few patient scenarios.
The panel shares tips for community oncologists who may not be familiar with treating patients with EV/pembro.
The panel shares their hopes for the future of bladder cancer treatment.
The panel kicked off with conversations about data released at ESMO, including EV-302 and CheckMate 901.
The panel shared their thoughts on the EV-302 study.
The panel discussed optimal treatment cycles for enfortumab vedotin/pembrolizumab.
How the potential shift of new therapies to the frontline setting will impact subsequent treatment decisions.
The panel discusses other exciting treatment advances in bladder cancer.
The panel shares predictions for the future of bladder cancer.
Uromigos Live & Unplugged: Prostate Cancer Roundtable
The panel discussed initial access issues with radioligand therapy, as well as interdisciplinary team collaboration.
The panel discusses recommended frequency of scans for patients receiving radioligand therapy, PSA response, and more.
The panel talks "pearls of wisdom" with radioligand therapy.
The panel discusses results of the phase 3 PSMAfore study presented at ESMO 2023.
The panel discuss patient interest in receiving radioligand therapy in the context of cost and access challenges.
The panel discusses treatment-related adverse events, including hematologic toxicities, xerostomia, and more.
The panel discussed the "innovative design" of the phase 2 ENZA-p study presented at ESMO 2023.
The panel shares insights on future advancements in the field.
Uromigos Live & Unplugged: Kidney Cancer Roundtable
The panel shared their approach to treatment selection for clear cell kidney cancer.
The panel reacts to the RENOTORCH study presented at ESMO and compares the frontline doublet treatment options for RCC.
The panel addresses the place for immune monotherapy, as well as takeaways from trials like PDIGREE, PROBE, and more.
The panel talks about non-clear cell kidney cancer, including treatment options and clinical trial data in this subgroup.
The panel discussed the results of the LITESPARK-005 trial, as well as the role of biomarkers in kidney cancer.
The panel shared thoughts on the TIDE-A study and best practices for starting and stopping TKI therapy in RCC patients
The panel discusses excitement for the future in kidney cancer: CAR-T, adjuvant checkpoint inhibitors, and sequencing.
Focus on Advanced Bladder Cancer
The panel discusses the approach to treating patients with cisplatin-eligible bladder cancer.
The panel discusses the approach to treating patients with cisplatin-ineligible bladder cancer.
The panel discusses patient characteristics and treatment sequencing considerations.
The panel discusses the approach to treating patients with platinum-ineligible bladder cancer.
The panel addresses treatment sequencing decisions following disease relapse.
The panel discusses the potential for more targeted treatments making their way into the advanced bladder cancer space.
The panel discussed how treatments used in the metastatic space are moving into the perioperative setting.
The panel discusses studies and areas of interest related to treatment options for advanced bladder cancer.
Focus on Frontline and Refractory RCC Treatment
The panel discusses the approach to frontline treatment selection for patients with RCC.
Dr. Rini describes the CLEAR and KEYNOTE-426 studies presented at ASCO 2023.
The panelists debate the use of IO/IO versus IO/TKI regimens for frontline RCC therapy.
The panel discusses toxicity management and use of precision medicine.
The panel discusses what is most exciting to them in the frontline RCC field.
The panel discusses treatment options in the refractory RCC setting.
The panel provides their concluding thoughts on the frontline and refractory RCC treatment landscape.
Focus on the RCC Treatment Spectrum
A panel discusses 4 frontline RCC treatment options.
The panel discusses considerations for treatment choice in patients with poor- and intermediate-risk disease.
The panel compares three TKI/IO treatment combinations.
The panel discusses outcomes from the CheckMate-9ER trial and addresses the importance depth of response.
The panel discusses the challenge of second-line RCC treatment options and how to sequence therapy.
The panel debates the "phenomenon" of rechallenging treatment in subsequent treatment lines.
The panel considers how to treat in the adjuvant setting following prior IO/IO or IO/TKI treatment.
The panel shares how they treat frontline papillary kidney cancer.
The panel discusses exciting ongoing clinical trials, including 304, TiNivo-2, PDIGREE, and more.
Focus on Frontline RCC Therapies
Dr. Rini is joined by a panel of RCC experts to discuss patient characteristics that impact treatment selection.
The panel discusses how they each approach debulking nephrectomy in their RCC patients.
The panel discusses monotherapy treatment for RCC.
The panel discusses which patients in their practices would be candidates for ipilimumab/nivolumab combination.
The panel discusses the CheckMate 8Y8 clinical trial.
The panel compares three treatment regimens.
The panel discusses treatment-related toxicities and when to consider stopping treatment.
The panel discusses the disappointing results of the COSMIC-313 trial.
The panel discusses triplet combinations in development for RCC.
The panel shares interesting clinical trial data in development, including CONTACT-03, TiNivo-2, and more.
Best of ASCO GU 2022 - Focus on Prostate Cancer
The panel discusses lutetium-177-PSMA for the treatment of advanced prostate cancer and reviews the VISION trial.
Drs. George and Sprenkle discuss PSMA PET scans, including challenges and the potential of Lutetium-based PSMA treatments.
The palliative benefits of lutetium-177 PSMA are discussed, including reduced symptom burden compared with standard of care.
Dr. Oliver Sartor weighs in on lutetium-177-PSMA as an effective therapy for prostate cancer.
Dr. Oliver Sartor and Dr. Rana McKay discuss some limitations (and advantages) of lutetium-177-PSMA.
Panel experts discuss PSMA-targeting agents currently being assessed, including PSMA-I&T-Lutetium-177.
Focus on PSMA Imaging
Drs. Agarwal and Calais review the basics of PSMA imaging of prostate cancer and what makes it unique.
Drs. Agarwal and Tward discuss the use of PSMA imaging for oncologists and urologists dealing with localized prostate cancer.
Drs. Agarwal and Tagawa discuss PSMA imaging and the future of CT scans in the follow-up of metastatic prostate cancer.
Drs. Agarwal and Tagawa discuss the VISION trial and how lutetium-177 PSMA-617 will be used to treat metastatic CRPC.
Drs. Agarwal, Calais, and Tward discuss the use of radiopharmaceutical-based therapeutics in patients with prostate cancer.
Knowledge Hub Spotlights
Curated clinical content based on conditions, therapies, and technologies
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.